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Abstract​: 
Delayed ischemic neurological deficit (DIND) is a major driver of adverse outcomes in patients 
with aneurysmal subarachnoid hemorrhage (aSAH) defining an unmet need for therapeutic 
development. Cell-free hemoglobin that is released from erythrocytes into the cerebrospinal fluid 
(CSF) is suggested to cause vasoconstriction and neuronal toxicity and correlates with the 
occurrence of DIND. Cell-free hemoglobin in the CSF of patients with aSAH disrupted dilatory 
NO signaling ex vivo in cerebral arteries, which shifted vascular tone balance from dilation to 
constriction. We found that selective removal of hemoglobin from patient CSF with a 
haptoglobin-affinity column or its sequestration in a soluble hemoglobin-haptoglobin complex 
was sufficient to restore physiological vascular responses. In a sheep model, administration of 
haptoglobin into the CSF inhibited hemoglobin-induced cerebral vasospasm and preserved 
vascular NO-signaling. We identified two pathways of hemoglobin delocalization from CSF into 
the brain parenchyma and into the NO-sensitive compartment of small cerebral arteries. Both 
pathways were critical for hemoglobin-toxicity and were interrupted by the large 
hemoglobin-haptoglobin complex that inhibited spatial requirements for hemoglobin reactions 
with NO in tissues. Collectively, our data show that compartmentalization of hemoglobin by 
haptoglobin provides a novel framework for innovation aimed at reducing hemoglobin-driven 
neurological damage after subarachnoid bleeding. 
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Introduction 
Aneurysmal subarachnoid hemorrhage (aSAH) represents 5–10% of all strokes and has an 
estimated global incidence of 6.67 per 100,000 people ​(1, 2)​. The loss of productive life years 
due to aSAH is as great as that for cerebral infarction because it frequently affects patients 
younger than 65 years of age ​(3)​. Delayed ischemic neurological deficit (DIND) complicates 
aSAH in one-third of cases and is a strong risk factor for unfavorable neurological outcomes 
defining an unmet need for therapeutic innovation ​(4, 5)​. 
Within days after aSAH, red blood cells in the CSF are disintegrated by immunological and 
non-immunological processes. This erythrolysis is a temporally variable process, which results in 
individual time profiles of cell free-hemoglobin (Hb) in the cerebrospinal fluid (CSF) ​(6)​. We 
previously reported that elevated concentrations of Hb in cerebrospinal fluid  correlate with the 
occurrence of DIND, which suggests that cell-free Hb accelerates pathological processes in 
patients with aSAH ​(6)​. Cell-free Hb has been discussed for many years as a driver of damage 
and as a cause of vasospasm after aSAH ​(7–9)​. However, the mechanisms of toxicity remained 
poorly defined, and no therapeutic strategy has been proposed to specifically neutralize the 
devastating effects of Hb on the brain.  
General mechanisms of cell-free Hb toxicity have been defined in models of systemic hemolysis, 
such as sickle-cell disease or after blood transfusion ​(10–14)​. The initial step of Hb toxicity is the 
dissociation of Hb-tetramers (64 kD) into small dimers (32 kD) and their delocalization into 
tissues ​(15)​. Once delocalized, cell-free Hb initiates tissue damage by free-radical reactions ​(16, 
17)​ and by nitric oxide (NO) depletion, which can cause vasoconstriction, ischemia and cardiac 
failure ​(10, 15, 18–20)​. NO-dependent signaling pathways are indispensable for functional and 
metabolic homeostasis of the brain ​(21–25)​. Due to the short half-life of NO in tissue, its 
signaling activity highly depends on the localization and compartmentalization of molecules that 
it can react with, such as cell-free oxyHb and deoxyHb ​(26–28)​. Disruption of endothelial NO 
signaling by cell-free Hb in cerebral arteries may cause vasospasms ​(29–33)​ and may facilitate 
microthrombosis by disinhibiting platelet adhesion and aggregation ​(34–36)​. Within the brain 
parenchyma, depletion of NO may lower the threshold for pathological electrical activity, which 
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leads to cortical spreading depolarizations ​(37, 38)​ and potentially dysregulates 
neuroinflammation ​(39, 40)​, and eventually result in DIND.  Despite the advanced scientific 
knowledge about the multifaceted pathogenesis of DIND, detection and treatment of 
angiographic vasospasm remains a pivotal factor in prevention of secondary neurological 
damage in aSAH patients ​(4, 41)​. 
Haptoglobin is the archetypical Hb scavenger protein in vertebrates, and irreversibly binds 
cell-free Hb in the plasma, forming a large protein-complex of >150 kD ​(42)​. In systemic 
hemolysis, haptoglobin blocks cell-free Hb extravasation and attenuates oxidative tissue toxicity 
and cardiovascular dysregulation that is triggered by Hb exposure ​(12, 15, 43–46)​. After aSAH, 
plasma-derived haptoglobin enters the CSF along with other plasma proteins ​(47)​. However, 
physiological quantities of haptoglobin cannot match the amount of cell-free Hb that is released 
by the erythrolytic process into the subarachnoid space, which results in uncontrolled cell-free 
Hb toxicity ​(47)​.  
In this study, we explored whether haptoglobin could neutralize the vasoconstrictive activity of 
cell-free Hb in CSF of patients with aSAH. Additionally, we developed a sheep model to provide 
proof-of-concept that haptoglobin administration into the CSF can prevent cell-free Hb mediated 
toxicity in the subarachnoid space providing a novel framework for therapeutic development. 
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Results 
Cell-free Hb in the cerebrospinal fluid of patients with aSAH is the major disruptor of 
arterial nitric oxide signaling 
In a clinical study we found that patients with DIND had higher cumulative cell-free Hb 
concentrations in CSF over a time period of 14 days after aSAH than patients without DIND ​(6)​. 
Vasospasm remains an important feature of DIND. Therefore, we wanted to define the role of 
cell-free Hb as a disruptor of vasodilatory arterial NO signaling in aSAH patients, and explore 
whether this toxic effect could be prevented by the Hb-binding properties of haptoglobin.  
We collected CSF samples between 1 and 14 days after subarachnoid hemorrhage from patients 
with aSAH and DIND. To define temporal changes in protein composition of CSF, we 
performed a quantitative liquid chromatography mass-spectrometry (LC-MSMS) proteome 
analysis of sequential CSF samples from three cases. Proteins identified by at least two unique 
peptides were classified into three categories by a k-means clustering analysis of the 
log-transformed and mean normalized ion intensity ratios (day x/day 1) ​(Figure 1A and 
supplementary data 1)​. Cluster 1 contained proteins whose log ratios remained unchanged over 
time, such as albumin. Cluster 2 represented proteins with log ratios that decreased. This group 
contained haptoglobin. Cluster 3 encompassed proteins with increasing log ratios. This group 
included many red blood cell components, namely Hb and erythrocyte enzymes. This finding 
illustrates the delayed erythrolytic process that occurs in the subarachnoid space after aSAH, 
coinciding with DIND. Within category 3, we have also detected high concentrations of ferritin 
light and heavy chains which indicates a localized adaptive macrophage response resulting in 
heme metabolism and iron detoxification. Endogenous haptoglobin was abundant in the initial 
samples but was depleted over time. These data suggest that a large fraction of unbound Hb 
accumulates over time in the CSF of patients with aSAH. 
An early clinical feature of DIND is the occurrence of vasospasms in cerebral arteries. Reactions 
of cell-free oxyHb (Fe​2+​O​2​) and deoxyHb (Fe​2+​) with the vasodilator NO may shift the balance 
towards vasoconstriction. To investigate this mechanism of dysregulation, we quantified the 
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NO-mediated vasodilatory responses ex vivo, using porcine basilar arteries immersed in human 
CSF samples. The expected dilatory response to administration of a short-lived NO donor 
(MAHMA-NONOate) was suppressed in arteries immersed in CSF that was collected from a 
patient during DIND at day 7 after aSAH, which contained a high concentration of cell-free Hb 
(Figure 1B)​. The physiological vasodilatory response to MAHMA-NONOate was restored when 
we selectively removed cell-free Hb from this CSF sample with an haptoglobin-affinity column 
(p<0.001 for comparison of maximal dilatory responses between conditions, for each condition 
n=12 dilation responses). Analyses of the CSF by LC-MS/MS before and after Hb removal 
demonstrated that the concentrations of other proteins in the CSF remained mostly unchanged by 
the haptoglobin-column ​(Figure 1C)​. This result confirmed that cell-free Hb is the disruptor of 
arterial NO signaling in the CSF of patients with aSAH and that this effect can be prevented by 
haptoglobin. ​Supplementary Figure S1​ shows that suppression of dilatory NO-signalling is 
dependent on the Hb concentration with complete suppression at concentrations exceeding 10 
μM oxyHb. 
 
Addition of haptoglobin to patient-derived CSF restores the vascular dilatory response to 
intrinsic and extrinsic nitric oxide 
In the next experimental step, we evaluated whether haptoglobin in solution could also restore 
Hb-disrupted arterial NO signaling ex vivo ​(Figure 1D)​. In these experiments, we investigated 
the effect of aSAH patient-derived CSF on the intrinsic vasomotor balance of porcine basilar 
arteries, followed by the assessment of the dilatory response to exogenous NO, and the effect of 
haptoglobin addition. 
We used a control CSF sample collected from a patient at day 0 after aSAH that contained no 
detectable cell-free Hb and CSF samples collected between days 4 -10 from two patients with 
severe DIND, which contained cell-free Hb of 17.2 µM and 26.8 µM oxyHb, respectively.  The 
vascular tension traces in ​Figure 1D ​ show that the basilar artery segments that were immersed in 
the erythrolysed patient-derived CSF produced a higher steady-state tension than the segments 
that were immersed in the non-erythrolysed control CSF, indicating that the endogenous vascular 
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NO pool was diminished when cell-free Hb was present. After the administration of a 
MAHMA-NONOate bolus, vessels that were immersed in erythrolysed CSF did not dilate, 
whereas vessels immersed in control CSF responded with a physiologic relaxation. Addition of 
haptoglobin (40 µM) to all samples did not have any effect on the tension of the artery segments 
that were immersed in control CSF, while the artery segments immersed in erythrolysed CSF 
slowly dilated until they reached the tension level of the controls. This slow dilation occurred in 
the absence of any exogenous NO donor, which suggests that haptoglobin restored an intrinsic 
vasodilatory pathway. At this point in the experiment, all arterial segments demonstrated an 
equal transient dilatory response to exogenous NO delivered by a bolus of MAHMA-NONOate. 
Haptoglobin restored the disrupted NO signaling effect of cell-free Hb. We then inhibited 
endogenous NO production with the NO-synthase inhibitor L-NIO (20 µM), which caused a 
slow contraction of all artery segments to the same steady-state level that was initially recorded 
with the basilar arteries exposed to erythrolysed patient-derived CSF. This contractile responses 
reflected the loss of a similar endogenous NO pool in all artery segments. 
To corroborate these observations, we further tested the ex vivo effect of haptoglobin using 
erythrolysed CSF collected from eight patients between days 4 - 10 after aSAH containing 
cell-free oxyHb concentrations between 11.5 µM and 49 µM (mean 19 µM, ±SD 12.5 µM). 
After the addition of haptoglobin, in a concentration that matched the cell-free Hb concentration 
in each sample, we observed a spontaneous dilation of the basilar artery segments in all 
patient-derived CSF samples until tensions reached approximately half of the initial values 
(Figure 1E)​. Haptoglobin also restored the vasodilatory response to exogenous NO to the level 
observed when using CSF that was sampled from the same eight patients at day 0 or day 1 after 
aSAH, before erythrolysis occurred ​(Figure 1F)​.  (Oneway ANOVA: p<0.001; Tukey-Kramer 
post test corrected for multiple comparison: p<0.001 for post-erythrolysed CSF versus the two 
other conditions and  p=0.94 between control CSF and post-haptoglobin CSF,  for each group 
n=8 dilation responses were performed). Size-exclusion chromatography (SEC) demonstrated 
that the addition of equimolar haptoglobin resulted in the binding of almost 100% of Hb in all 
patient samples as demonstrated by the shifted heme elution profile ​(Figure 1G) ​. 
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Collectively, these data demonstrate that Hb is the main disruptor of arterial NO signaling in the 
CSF of patients with aSAH, and that it remains accessible to binding and neutralization by 
haptoglobin. 
 
Haptoglobin halts Hb-induced cerebral vasospasms in sheep 
To validate our approach of using haptoglobin to reverse Hb-mediated cerebral artery 
vasospasms in vivo, we established a sheep ventricular infusion model. In this model, the 
distribution of Hb and Hb-haptoglobin complexes could be visualized by T1-weighted magnetic 
resonance imaging (MRI) and vasospasms could be monitored by selective cerebral digital 
subtraction angiography (DSA). We slowly infused artificial CSF, or solutions containing Hb, 
haptoglobin or Hb-haptoglobin complexes into the frontal horn of the left lateral ventricle 
(Figure 2)​. The intracranial pressure was continuously monitored to avoid its uncontrolled 
change during the experiment ( ​supplementary Figure S2).​ Minutes after infusion, the 
hemoproteins appeared in the CSF, which drained from a suboccipital spinal cannula indicating a 
rapid distribution from the lateral ventricle into the external CSF compartment (i.e., the 
subarachnoid space). The distribution of cell-free Hb and Hb-haptoglobin complexes was 
visualized by MRI after replacing iron-protoporphyrin (FePP) in the hemoproteins with 
manganese-protoporphyrin (MnPP) ​(Figure 2A)​. The T1-weighted MRI images confirmed that 
the Hb(MnPP) and Hb(MnPP)-haptoglobin complexes were distributed equally throughout the 
ventricular system, the cisterna magna and the basal subarachnoid space ​(Figure 2B and 
supplemental movies M1-M3)​. Twenty minutes after infusion, a robust MnPP signal at the base 
of the brain visualized the arterial circle of Willis immersed in CSF containing a high 
concentration of hemoproteins ​(Figure 2 D/E) ​. These results confirmed that our ventricular 
infusion model effectively distributed Hb and haptoglobin into the subarachnoid space. 
We then used the sheep ventricular infusion model to assess the effect of cell-free Hb on vascular 
tone in vivo ​(Figure 3A)​. Selective cerebral angiography performed after the infusion of a 5 ml 
bolus of cell-free oxyHb (HbFe ​2+​O​2​, 5 mM) into the ventricular CSF demonstrated segmental 
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vasospasms in different arteries in angiographies recorded after 45 min and 60 min ​(Figure 3B 
and Figure 4A)​, which coincided with drainage of cell-free Hb from the subarachnoid space as 
recorded by SEC ​(Figure 3A) ​. To test whether cell-free Hb in the subarachnoid space was 
accessible for binding and neutralization by haptoglobin, we administered a concentrated 
haptoglobin solution (5 ml, 4 mM) into the lateral ventricle of a sheep previously infused with 
Hb. Within minutes, 100% of cell-free Hb was bound to haptoglobin, forming Hb-haptoglobin 
complexes (as indicated by SEC); subsequently, Hb-induced vasospasms soon resolved. 
The experimental approach with sequential injection of Hb and haptoglobin into sheep CSF has 
several limitations, such as different time points in the experiment at which we evaluated 
vasospasms before and after haptoglobin infusion, as well as possibly heterogeneous dilution 
effects (i.e., the haptoglobin solution dilutes the Hb in CSF). To overcome these limitations, we 
repeated the experiments with injection of a 2.5 ml bolus of either Hb or Hb-haptoglobin 
complexes at equal concentrations (3 mM heme) and visualized the cerebral vascular 
morphology by DSA 60 minutes after injection for quantitative analysis of vasospasms. 
Segmental vasospasms occurred in 4 out of 4 sheep injected with Hb, whereas no vasospasms 
were detected in 4 sheep injected with Hb-haptoglobin complexes ​(Figure 4B)​. We performed a 
blinded and semiautomatic quantitative analysis of arterial diameters in the DSA images of four 
ex-ante defined cerebral artery regions to objectify the visual impression of vasospasms 
(supplementary Figure S3) ​. We found a significant narrowing of the basilar artery, the anterior 
and middle cerebral arteries, as well as of the cisternal internal carotid artery in Hb-infused 
animals compared with those in Hb-haptoglobin infused animals ​(Figure 3C) ​. Hb-induced 
vascular contractions became even more apparent in a pooled analysis of all arterial segments 
(Figure 3D)​. The Hb-induced reduction in cerebral artery diameters appeared to be moderate 
(15%). However, considering that the resistance (R) of a vessel is inversely proportional to the 
fourth power of its radius (R ~ 1/r​4​), a 15% reduction in arterial diameter doubles the vascular 
resistance in these segments. We found no significant change in arterial diameters after 
Hb-haptoglobin infusion or after infusion of an equal volume of artificial CSF, which was 
performed as a general control procedure during the initial phase of each experiment ​(Figure 
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3D)​. These results showed that cell-free Hb causes vasospasms accompanied by a reduction in 
arterial diameters and that this was reversed by binding of Hb to haptoglobin.  
To assess whether the recovery of Hb-induced vasospasms by haptoglobin was related to effects 
on vascular NO signaling, we quantified NO-mediated arterial dilation ex vivo using porcine 
basilar artery segments immersed in sheep CSF sampled from the subarachnoid space of the 
sheep used in the previous experiments, immediately after angiography ​(Figure 3E)​. We found 
that CSF from Hb-infused sheep (200-240 µM Hb) completely suppressed the dilatory response 
to MAHMA-NONOate. In contrast, the dilatory response in CSF from Hb-haptoglobin infused 
animals (200-240 µM Hb-haptoglobin) was intact and not different from the physiological 
response recorded in CSF samples collected after the injection of artificial CSF. Finally, we 
explored whether haptoglobin could restore physiological responses in arteries rendered 
unresponsive to NO by previous immersion in CSF from Hb-infused animals. When adding 
haptoglobin to such an equilibrated system at quantities that matched the concentration of 
cell-free Hb, physiological responses of the cerebral arteries to NO were re-established within 
minutes (​Figure 3F ​). Comparison of the maximal vasodilatory responses revealed a significant 
difference between the Hb CSF and all other groups (p<0.0001, n = 4 per group). These results 
are in concordance with the outcome of our initial in vivo experiment where delayed 
administration of haptoglobin into the ventricular CSF reverted cell-free Hb-induced 
vasospasms. 
Collectively, the functional data obtained in our sheep model demonstrate that haptoglobin 
administration into the CSF could bind cell-free Hb in a Hb-haptoglobin complex restoring 
vascular NO signaling and cerebral artery dilation.  
 
Hb and the Hb-haptoglobin complex have identical NO reaction kinetics in the 
subarachnoid space 
The reaction of oxyHb with NO is the fundamental mechanism that causes Hb-induced 
vasospasms in our model. NO reacts with oxyHb in a three-step reaction ​(Figure 5A) ​(27)​. We 
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have previously reported estimates for the NO reaction kinetics of oxyHb bound to haptoglobin 
(15)​. However, these experiments were performed under conditions of Hb excess over NO, and 
therefore captured only the first step of the reaction, which oxidizes oxyHb(Fe ​2+​) to metHb(Fe​3+​) 
consuming one NO molecule. In the current study, we compared NO reaction kinetics of 
cell-free Hb and Hb-haptoglobin complex using an excess concentration of NO, which allows us 
to follow the sequence of reactions. ​Figure 5B​ shows absorbance changes at 405 nm of Hb and 
the Hb-haptoglobin complex after rapid mixing with NO in a stop-flow instrument. We used a 
glutaraldehyde polymerized Hb as a control compound that mimics the large size of the 
Hb-haptoglobin complex lacking the additional protein component of haptoglobin. The 
absorbance data could be best approximated by a function expressed as a sum of three 
exponentials, which mathematically supports the three step reaction mechanism ​(supplementary 
Figure S4A/B) ​. The calculated rate constants for k1 and k2 confirm that the NO-reaction is very 
similar for all three hemoprotein. In another stop-flow experiment we compared the reaction of 
NO with CSF that was recovered from subarachnoid space of sheep after intraventricular 
infusion of Hb or Hb-haptoglobin complex. This experiment demonstrates that haptoglobin does 
not change the biochemical reaction of Hb with NO in the subarachnoid space, as long as the 
hemoprotein remains accessible for NO ​(supplementary figure S4C/D)​. 
 
Large molecular size of the Hb-haptoglobin complex preserves dilatory NO-signaling in 
porcine basilar arteries and prevents translocation of the NO-reactive complexes into the 
brain 
In light of the very divergent effect on vascular NO-signaling, the identical NO reaction kinetics 
of cell-free Hb and the Hb-haptoglobin complex appear to be contradictory. We have therefore 
used the above described polymerized Hb, which differs from cell-free Hb only by its large size, 
to explore a molecular-size dependent protection of vascular NO signaling in cerebral arteries. 
NO-mediated relaxation of basilar artery segments was completely interrupted by Hb, but it 
remained intact in the presence of equal concentrations of the Hb-haptoglobin complex or 
polymerized Hb ​(Figure 5C) ​.The differential effects of the three hemoproteins on vascular 
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responses were mirrored by the divergent ability of the proteins to translocate from the 
subarachnoid CSF space into the brain parenchyma ​(Figure 5D)​. For these mechanistic studies 
we injected trans-cyclooctene (TCO) labelled Hb, Hb-haptoglobin, or polymerized Hb into the 
subarachnoid space of mice. TCO is a small tag, which can be visualized with a high 
signal-to-noise ratio on 120 µm vibratome sections after a click-chemistry reaction with 
Cy5-conjugated tetrazine. ​Figure 5D​ shows that the small cell-free Hb delocalizes within two 
hours from the subarachnoid space deep into the mouse brain. This is in contrast to the 
Hb-haptoglobin complex and the polymerized Hb, which remained completely excluded from 
the brain parenchyma. In the brains of the Hb-haptoglobin and polymerized Hb injected animals 
positive fluorescence signals were only detected in the region of the injection trajectory. ​Figure 
5E​ shows SEC-HPLC elution profiles of the three hemoproteins demonstrating the small size of 
Hb, and the large size of Hb-haptoglobin complexes and polymerized Hb, respectively. From 
these studies, we hypothesized that size-restricted barriers may limit translocation of the 
Hb-haptoglobin complex from the subarachnoid CSF space into NO sensitive compartments of 
the cerebral vasculature and the brain. 
 
Haptoglobin blocks translocation of cell-free Hb from CSF to brain parenchyma and blood 
vessels in sheep 
In a next experimental step, we infused trans-cyclooctene (TCO)-tagged Hb or Hb-haptoglobin 
complexes into the CSF of sheep to further analyze distribution and translocation patterns of Hb 
in the brain and the cerebral vasculature. The fluorescence scans of 120 µm sheep brain sections 
at two different sites of the forebrain and midbrain demonstrated that within 2 hours after 
infusion, the cell-free Hb delocalized from the internal and external CSF spaces into the brain 
parenchyma, appearing as a rim of fluorescence signal along the internal and external CSF−brain 
interfaces ( ​Figure 6A, left​). This pattern of delocalization was absent in sheep brain sections that 
were infused with TCO-Hb-haptoglobin complexes (​Figure 6A, right ​). For the illustration of the 
Hb-haptoglobin complex distribution in ​ Figure 6A​, we chose a section of the forebrain where 
the tip of the ventricular catheter was placed slightly into the brain parenchyma. At this location, 
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a small quantity of TCO-Hb-haptoglobin was directly injected into the brain tissue, serving as a 
positive control for the staining and imaging procedure. In addition, the only distinct 
Hb-haptoglobin signal could be recognized alongside small arteries penetrating from the pial 
surfaces into the brain. Before sacrificing the sheep, we collected CSF from the subarachnoid 
space for SEC and SDS-PAGE analysis. Despite the absence of an Hb-haptoglobin signal in 
brain sections, we identified the large Hb-haptoglobin complex by SEC and SDS-PAGE in the 
CSF, which was sampled at the end of the experiment before sacrificing the animal (​Figure 
6B/C​). Collectively, these data support that cell-free Hb translocates from the CSF to the brain 
parenchyma and that the Hb-haptoglobin complex remains compartmentalized in the CSF space. 
In a next series of imaging studies, we evaluated whether cell-free Hb could translocate from the 
CSF into the vascular smooth muscle cell layer of cerebral arteries, where NO mediates its 
vasodilatory signal. This translocation may be a key pathophysiological pathway for cell-free Hb 
acting as a cerebral artery vasoconstrictor, which could be blocked for the large Hb-haptoglobin 
complex. For examination of vascular structures by confocal microscopy, sheep brain sections 
from animals infused with TCO-Hb or TCO-Hb-haptoglobin were stained for vascular smooth 
muscle cells and for the aquaporin-4-positive astrocyte end-feet and confocal micrographs of 
several small arteries of different calibers in the periventricular area of the midbrain were taken. 
Cell-free Hb delocalized across the astrocyte barrier into the brain tissue and additionally into the 
vascular smooth muscle layer reaching the subendothelial space ( ​Figure 7​). By contrast, the 
Hb-haptoglobin complex remained compartmentalized at a high concentration within the 
CSF-filled perivascular space (Virchow-Robin space) of penetrating arteries. This space is 
delineated by the outermost layer of the arteries (i.e. the adventitia) on one side and by the 
astrocyte end-feet on the other side (i.e. the glia limitans). These observations likely explain why 
cell-free Hb but not the large Hb-haptoglobin complex interrupts vasodilatory NO signaling in 
cerebral arteries and thereby induces vasospasm. 
To link the observed perivascular Hb exposure of small parenchymal vessels (diameter range of 
50 -100 μm) to the functional readouts for large cerebral arteries, we have performed a 
histomorphometric analysis. For this purpose, we have stained 120 µm sheep brain sections 
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through the fourth ventricle for smooth muscle cells ​(Supplementary Figure S5A)​. Confocal 
images of the small alpha-smooth muscle actin (αSMA)-positive vessels in the tela choroidea 
were acquired by a researcher blinded to the treatments (n=3 sheep per group, a total of 25 
images of Hb-treated sheep, 32 images for Hb-haptoglobin-treated sheep). We have chosen the 
periventricular area for this analysis because this tissue is very rapidly exposed to the 
intraventricularly instilled fixative, ensuring excellent structural preservation after euthanasia. 
For each vessel, the lumen and total cross-sectional areas were quantified based on the inner and 
outer circumference of the αSMA positive structures, which were manually determined by three 
blinded researchers ​(Supplementary Figure S5B)​. While vessels with a contracted appearance 
were abundant in all Hb infused animals, none could be found in Hb-haptoglobin infused 
animals ​(Supplementary Figure S5C)​. ​Supplementary Figure S5D and E ​ show the 
quantitative analysis of the luminal fraction areas of all analysed vessels, as well as the mean per 
sheep. In both ways of analysis, the differences were statistically significant with smaller 
fractional lumen areas of Hb compared to Hb-haptoglobin treated animals. 
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Discussion 
In patients with aSAH, erythrolysis in the subarachnoid space leads to an accumulation of 
cell-free Hb exceeding haptoglobin scavenger capacity in the CSF. We confirmed that this 
unbound Hb is the principal dysregulator of vascular NO signaling, and thus promotes spasms in 
cerebral arteries and smaller parenchymal arterioles. Our results show that delocalization of 
cell-free Hb from CSF into vascular structures is the primary cause of this pathophysiology, 
which can be prevented by size-dependent compartmentalization of Hb in the CSF by the 
formation of large Hb-haptoglobin complexes. We further identified delocalization of Hb into 
the brain parenchyma as another pathway of Hb induced pathophysiology which is also blocked 
by haptoglobin. These observations suggest that haptoglobin may control a spectrum of oxidative 
and NO-related toxicities that have been associated with cell-free Hb, heme and iron exposures 
within the brain ​(Figure 8)​. 
We found no NO-depleting or vasoconstrictive activity in human CSF samples collected from 
patients shortly (1 or 2 days) after the inciting bleeding event. In contrast, samples collected at 
later phases of the disease displayed an erythrolysed protein signature that disrupted NO 
signaling and shifted vascular tone balance towards vasoconstriction. Selective removal of Hb 
from patient-derived CSF by a haptoglobin-column was sufficient to abate this activity. 
Furthermore, the collective experimental data presented here suggest that a therapeutic 
intervention targeting compartmentalization of Hb within the CSF might be sufficient to prevent 
cerebral vasospasm. The slow time-course of Hb accumulation in CSF after the inciting bleeding 
event provides a window of opportunity to restore the Hb binding capacity of CSF by exogenous 
haptoglobin. 
The protective physiological effect of haptoglobin during systemic hemolysis has been related to 
the large molecular size of the Hb-haptoglobin complex ​(15, 43)​. The complex is too large to be 
filtered by the kidney or to extravasate from blood into the wall structures of coronary arteries or 
the interstitial space of the myocardium ​(15, 48)​. These observations helped to resolve the 
enigma that the biochemical reactivity, which was recognized as the source of cell-free Hb 
toxicity, was not substantially different in the case of the Hb-haptoglobin complex compared 
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with unbound Hb. According to the compartmentalization hypothesis, the potentially detrimental 
peroxidase and dioxygenase reactions of Hb remain uneventful as long as they occur within the 
circulatory plasma compartment. Here, we could extend and reinforce this hypothesis in 
experiments mimicking intracranial conditions, which are fundamentally different from the 
models of intravascular hemolysis that we have studied before.  
In patient and sheep CSF, the reaction kinetics of cell-free Hb and the Hb-haptoglobin 
complexes with NO were similar, even though we adapted our experimental conditions to model 
the full three-reaction kinetics of Hb with NO depicted in ​figure 5B ​and​ Supplementary Figure 
S4​. However, we discovered that haptoglobin was able to block two divergent pathways of 
cell-free Hb delocalization from CSF. First, haptoglobin prevented translocation of cell-free Hb 
from the CSF  into the smooth muscle layer and subendothelial space of arterial vessels. We 
assume that the size-restricted interruption of this delocalization path by haptoglobin spatially 
separates the Hb-haptoglobin from functional NO and thus preserves vascular NO signaling, 
preventing vasospasms in small and large cerebral arteries. The finding that chemically 
crosslinked Hb-polymers - with a large molecular size but unaltered NO-reactivity compared to 
Hb - did not only mimic the spatial compartmentalization effect of the Hb-haptoglobin complex, 
but also showed the same NO-sparing effect in ex vivo vascular function studies, supported this 
assumption. Second, haptoglobin prevented translocation of cell-free Hb through the inner and 
outer CSF-brain barrier into the brain interstitial space, i.e., through the ependymal layer and glia 
limitans ​(49, 50)​. Again, we found no evidence that the Hb-haptoglobin complex could cross this 
anatomical barrier, which is permeable to proteins up to 70 kDa ​(49, 50)​. Prevention of Hb 
delocalization into the brain’s interstitial space may avert Hb-triggered oxidative stress to neural 
tissue ​(43, 51)​ and spare NO signaling within the neurovascular unit. Furthermore, prevention of 
this delocalization may reduce Hb-triggered microthrombosis ​(34–36)​, neuroinflammation ​(39, 
40)​, and pathological electrical activity, i.e., cortical spreading depression (CSD) ​(37)​. 
Vasodilatory NO signaling can be disrupted at several levels after aSAH ​(41, 52)​. Our studies 
focused on the sink-theory, by which oxyHb reacts with NO and depletes the vasodilator within 
the vascular wall or in neuronal tissues. Several other mechanisms of NO dysfunction have also 
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been demonstrated; however,  the quantitative contribution toward pathophysiology continues to 
be defined. Perivascular nerve fibers expressing nitric oxide synthase (NOS) amongst other 
vasoactive substances are critical for the regulation of cerebral arterial vascular tone ​(53, 54)​. 
These NOS expressing neurons disappear after aSAH, presumably as a result of Hb and heme 
toxicity ​(55, 56)​. It has also been observed that the endogenous NOS inhibitor asymmetric 
dimethyl arginine (ADMA) accumulates in CSF after aSAH ​(57)​. 
Additionally, Hb, heme, and heme-degradation products can exert vascular effects via NO 
independent mechanisms. Oxidation of bilirubin, the ultimate heme-metabolism product, results 
in the accumulation of bilirubin oxidation products (BOXes) and propentdyopents in patient CSF 
(58–60)​. Heme, BOXes, and propentdyopents can all promote vasoconstriction by acting on 
large conductance BK​Ca​ potassium channels in astrocytes and vascular smooth muscle cells 
(60–62)​. Finally, oxyHb can stimulate production of the potent vasoconstrictor, endothelin ​(63, 
64)​, and alter expression of calcium and potassium channels in cerebral arteries ​(65–67)​. 
Cell-free Hb and heme may also accelerate acute and chronic inflammatory processes promoting 
more chronic disruption of vascular homeostasis, which occurs alongside the NO-depletion 
related vasoconstriction after aSAH ​(68)​.  
In relation to the NO sink-framework, the protective mechanism underlying our observations is 
related to the large molecular size of the Hb-haptoglobin complex restricting access of cell-free 
Hb to NO sensitive structures in the vascular wall. Haptoglobin demonstrates additional 
protective functions, which are related to its structural stabilization of bound Hb molecule 
dimers. We have shown that free radicals are stabilized and less reactive in the Hb-haptoglobin 
complex compared to free Hb ​(69, 70)​, that the complex has an enhanced resistance against 
oxidative damage ​(71, 72)​, and that the oxidant heme cannot be released and transferred from 
Hb-haptoglobin to lipid compartments ​(73)​. In many experimental models, these functions of 
haptoglobin translate into anti-oxidant and cytoprotective effects ​(44, 74, 75)​. It remains to be 
investigated how these additional functions of haptoglobin may protect against a broader range 
of Hb and heme driven pathologies after aSAH 
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We noted several limitations of our study that need to be addressed before an haptoglobin-based 
therapy can be further developed for a clinical trial  in patients with aSAH. First, our studies 
were designed to dissect the toxicity of cell-free Hb in CSF as a distinct and targetable 
pathophysiological factor potentially accelerating the development of secondary neurological 
damage after aSAH. Our models do not account for mechanisms of early brain injury (EBI) 
caused by aneurysm rupture in aSAH patients ​(41, 76)​. Interspecies differences and mode of 
bleeding induction are known to limit translation of animal model data in SAH research to 
clinical practice ​(77)​. We have tried to compensate for this limitation by the use of different 
species and the use of CSF samples of aSAH patients in ​ex vivo​ vascular function experiments. 
Various haptoglobin phenotypes occur in humans. Haptoglobin 1-1 is a homodimeric molecule 
with a molecular size of 84 kD without bound Hb and 148 kD with two Hb dimers bound at each 
pole of the protein ​(42)​. Haptoglobin 2-2 and haptoglobin 2-1 are heterogeneous mixtures of 
larger polymers. Earlier hypotheses that outcomes of aSAH depended on haptoglobin phenotypes 
have been refuted ​(78)​, and our own studies could not reveal significant biochemical or 
physiological differences between the binding and detoxifying effects of haptoglobin 1-1 and 
haptoglobin 2-2 in vitro or in the systemic circulation of guinea pigs ​(79)​. In this study, we used 
a plasma-derived haptoglobin product, which is almost exclusively composed of larger 
haptoglobin polymers (haptoglobin 2-2 and haptoglobin 2-1). Therefore, we cannot make 
predictions regarding the functionality of haptoglobin 1-1 to detoxify cell-free Hb in the CSF. A 
homodimeric product, plasma-derived or recombinant, may be advantageous as a therapeutic 
compound compared to the heterogenous mixture of Type 2-2 polymers because it could be 
better characterized and may be formulated at a higher concentration with less aggregation and 
viscosity. These features may prove to be a critical advantage for a tightly volume-restricted 
intrathecal administration. However, since compartmentalization due to large molecular size 
proved to be the definite mechanism of protection, a careful comparison of the protective effect 
of the smaller haptoglobin 1-1 versus the larger haptoglobin 2-2 needs to be carried out. 
Another open question that needs to be addressed relates to the clearance of  Hb-haptoglobin 
complex from the CSF. We assume that a large proportion of the Hb-haptoglobin complexes 
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formed in vivo could be removed by CSF drainage. However, we still expect that some 
Hb-haptoglobin complexes would be retained in more secluded areas of the subarachnoid space, 
such as within the widely ramified Virchow-Robin spaces. Macrophages clear Hb-haptoglobin 
complexes by the CD163 scavenger receptor, and have a high capacity to metabolize heme by 
heme-oxygenase ​(80, 81)​. However, few studies have addressed this clearance pathway in the 
CSF compartment ​(47)​, and it will be critical to further elucidate its efficiency after therapeutic 
haptoglobin supplementation. Additionally, it will be essential to understand how 
Hb-haptoglobin clearance may modulate macrophage phenotypes and inflammatory functions. 
The last question relates to the technical feasibility of our concept. The typical bleeding volume 
in aSAH is 35 ml ​(82)​, which contains 4-5 grams of cell-free Hb. We expect that an optimized 
therapeutic formula should contain at least 100 mg/ml of active haptoglobin, and 40-50 ml of 
such a therapeutic formula should be administered into the CSF of a patient during a treatment 
course if all Hb in the clot should be captured. Although this volume seems large, the slow 
erythrolysis over several days provides a significant time window for a fractionated dosing 
schedule. Furthermore, the HPLC and wire-myography methods that we describe in this paper 
may support personalized dosing schemes based on functional target effects. Finally, we do not 
know how haptoglobin may be distributed within the subarachnoid space when a subarachnoid 
blood clot compromises physiologic flow and free diffusion in the CSF. Mechanical obstruction 
would likely reduce the accessibility of cell-free Hb within the clot and in the vicinity of the 
culprit blood vessel ​(83)​. However, as demonstrated in our patients and in the sheep model, 
cell-free Hb distributes in the CSF after erythrolysis, well beyond the site of the initial bleeding 
with potentially far-reaching toxic effects, and we consider this fraction of Hb as the accessible 
target of an haptoglobin-based therapeutic formula. 
Future treatment strategies to improve neurological outcomes after aSAH will likely leverage the 
synergistic effects of multiple drugs. Currently, the calcium channel blocker nimodipine is the 
only drug approved for DIND prevention in the US and Europe ​(84, 85)​. Despite ambiguous 
scientific evidence, intra-arterial mechanical or chemical angioplasty is generally accepted as 
rescue therapy for selected patients with DIND and refractory cerebral vasospasms ​(84, 85)​. 
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Endothelin receptor blockers reportedly reversed angiographic vasospasms in clinical trials but 
failed to improve neurological outcomes ​(86, 87)​,​ likely because of the significant systemic 
adverse effects. Additionally, therapeutic approaches limited to reversal of large arteries 
vasospasm may not sufficiently address the cascading pathophysiology of DIND, which starts 
with the rupture of the aneurysm leading to early brain damage  ​(41, 76, 88)​, and which is 
subsequently amplified by secondary hits such as accumulation of cell-free Hb in CSF. 
Based on the recognized importance of dysfunctional NO-signaling in the pathophysiology of 
vasospasm and DIND, there remains a keen interest in the use of NO-donors as preventive or 
rescue therapies. NO can be delivered by systemic administration of NO-releasing molecules 
such as sodium nitroprusside, nitroglycerin, molsidomin or NONOates, by inhalation of NO gas, 
or locally, either via an arterial catheter during angiography or into the CSF ​(89–91)​. In mice 
inhalation of NO reduced microvascular vasospasm, attenuated brain damage, and improved 
neurological outcome in an experimental model of SAH ​(92)​. Nitrite is another NO donor, which 
liberates NO in a reaction with deoxygenated Hb ​(93)​. Intravenous nitrite was effective in 
preventing and reversing cerebral artery vasospasm in a primate model of SAH, and 
demonstrated an acceptable side effect profile in human ​(33, 94, 95)​. Hypothetically, the local 
NO sparing effect of haptoglobin may support the concomitant use of NO donors or other 
vasodilatory drugs, leveraging synergistic activities. Furthermore, the strong Hb-stabilizing and 
antioxidant functions of Hp may alleviate prooxidant adverse effects of metHb formation that is 
associated with the use of NO-donors ​(73, 96)​. 
In summary, we defined Hb delocalization from CSF into cerebral vasculature and brain 
parenchyma as the most upstream mechanism of Hb toxicity after aSAH. Therapeutic 
haptoglobin supplementation compartmentalizes Hb in CSF and restores the physiological NO 
signaling in cerebral vasculature, which shifts the balance towards vasodilation. We conclude 
that intraventricular haptoglobin administration may present a useful therapeutic approach to 
reduce the toxicity of cell-free Hb in patients with hemorrhages into CSF.  
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Methods 
Hemoglobin, haptoglobin, Hb-haptoglobin complexes and polymerized hemoglobin: 
Hemoglobin (Hb) was purified from sheep blood or expired human blood concentrates as 
previously described ​(97)​. Hb concentrations were determined by spectrophotometry as 
described and are given as molar concentrations of total heme (1 M Hb tetramer is, therefore, 
equivalent to 4 M heme) ​(73)​. For all Hb used in these studies, the fraction of ferrous oxyHb 
(HbFe​2+​O​2​) was always > 98% as determined by spectrophotometry, unless stated otherwise. 
Haptoglobin from human plasma (phenotype 2-2 predominant) was obtained from CSL Behring 
(Bern, Switzerland). The identity, purity, and function of the protein were confirmed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), PAGE, and SPR as previously 
described ​(79, 98)​. Hb binding capacity of the haptoglobin was quantified with SEC 
chromatography. After complex formation the purity of the complex and the absence of free Hb 
was verified using SEC chromatography. 
Polymerized bovine Hb was prepared at a 40:1 molar ratio of glutaraldehyde to human Hb as 
described ​(99)​. The preparation of MnPP-Hb and MnPP-Hb-haptoglobin complexes is described 
in the supplement.  
CSF samples from patients with aSAH: ​Patients with radiological high-grade (Fisher grade 3 or 
4) aSAH and external ventricular drain insertion who were admitted to our Neurocritical Care 
Unit, University Hospital of Zurich (an academic tertiary care center) between April 2017 and 
December 2018 were included in a consecutive study approved by the local ethical review board 
of the canton of Zurich. Written consent was obtained from all patients or their legal 
representatives before study inclusion.  
HPLC measurements: ​Samples containing Hb and/or Hb-haptoglobin were separated on an 
analytical BioSep-SEC-s3000 (600 × 7.8 mm) LC column coupled with a BioSep-SEC-s3000 
(75 × 7.8 mm) Guard Column (Phenomenex, Torrance, CA). Details are provided in the 
supplement. 
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Proteomics of CSF samples: ​The proteomics workflow including sample preparation, 
LC-MSMS analysis is described in the supplementary methods section. 
Measurement of Hb−NO reaction by stopped-flow spectrophotometry: ​The HbO​2​ reaction with 
NO was measured with a SX18MV stopped-flow spectrophotometer (Applied Photophysics Ltd., 
Leatherhead, UK) ​(100)​. Details of the measurement and data analysis are provided in the 
supplement. 
Ex vivo vascular function experiments: ​Vascular function experiments were performed in a 
Multi-Channel Myograph System 620 M (Danish Myo Technology, Aarhus, Denmark) as 
described in the supplement. The NO-mediated vasodilatory responses were induced by the 
addition of MAHMA-NONOate (ENZO Life Sciences, Lausen, Switzerland). If not otherwise 
stated, the recorded hemoglobin-induced vascular function responses were normalized relative to 
maximum NO dilatation without Hb exposure (= 100%) and the level of tonic contraction before 
addition of MAHMA-NONOate (= 0%), respectively, during a single experiment.  
Sheep model: ​Animal studies were conducted according to the Swiss legal requirements for 
animal protection and welfare (TschG 455) and received ethical approval from the cantonal 
veterinary authorities ‘Kantonale Tierversuchskommission Zürich’ (permission No ZH234/17). 
Swiss alpine sheep,  age 2-4 years, were obtained from the Staffelegghof (Küttigen bei Aarau, 
Switzerland).  
Under general anesthesia, female ventilated sheep were instrumented with a left frontal external 
ventricular drain (DePuys Synthes, Oberdorf, Switzerland) a suboccipital spinal needle 
(Dalhausen, Köln, Germany) for CSF sampling from the subarachnoid space and a right frontal 
multimodal neuromonitoring probe (Luciole Medicale AG, Zurich, Switzerland). Illustration of 
the experimental setup is provided in ​supplemental Figure S6 ​. For controlled ventricular 
injections of aCSF, Hb, haptoglobin or Hb-haptoglobin complexes, a PHD Ultra syringe pump 
(Harvard Apparatus, Holliston, USA) was connected to the EVD. Ventricular injections were 
performed with maximal flow rates of 30 ml/h and ICP maintained constant. A detailed 
description of the model is provided in the supplementary methods. 
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Digital subtraction angiography (DSA): ​Digital subtraction angiography was performed in an 
Allura Clarity angiography suite (Philips, Hamburg, Germany) with angiographic 5F catheter 
(Cordis, Bar, Switzerland) placed into the largest anastomosis between the right maxillary artery 
and the extradural rete mirabile. Details of the procedure, image processing and data analysis are 
provided in the supplementary methods and in ​Figure S3 ​. 
Magnetic resonance imaging: ​In vivo​ magnetic resonance imaging was performed in a clinical 3 
Tesla MRI unit (Philips Ingenia, Amsterdam, Netherlands). Details are provided in the 
supplement.  
Mouse Model:​ ​Wild-type male C57BL/6J mice (10-12 weeks, total n = 9) were obtained from 
Charles River (Sulzfeld, Germany) and maintained at the animal facility of the University of 
Zurich (LASC) and treated in accordance with the guidelines of the Swiss Federal Veterinary 
Office. The studies were conducted according to the Swiss legal requirements for animal 
protection and welfare (TschG 455) and received ethical approval from the cantonal veterinary 
authorities ‘Kantonale Tierversuchskommission Zürich (permission No ZH073/17). Details of 
the stereotactic injection model and sample preparation are provided in the supplement. 
Histology: ​Details of sample preparation and staining procedures including identity of antibodies 
are provided in the supplement.  
Statistics: ​We used JMP software from SAS (versions 13 or 14) for all analyses. Data are 
presented with all data points plotted. Overlayed diamonds represent mean, 95% CI, and ​overlap 
marks (horizontal lines above and below the mean-line), which define statistical significant 
difference between groups if not overlapping (p<0.05). Groups were compared with  1-way 
ANOVA applying a Tukey-Kramer post-test correcting for multiple comparisons. A p-value of 
less than 0.05 was considered statistically significant. 
Study approval: ​All animal studies were approved by the cantonal veterinary authorities 
‘Kantonale Tierversuchskommission Zürich’. The clinical study (CSF sampling) was approved 
by the local ethical review board of the Kanton of Zurich, and written consent was obtained from 
all patients or their legal representatives. 
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Figure 1: Haptoglobin restores Hb-disrupted nitric oxide signaling in cerebral arteries.  
A​  K-means clustering of CSF proteins of three patients collected at day 1, 4, 7, 11, and 14 after 
aSAH. The right panel shows a principal component analysis of the identified proteins. Cluster 1: 
proteins remaining unchanged (ALB: albumin). Cluster 2: proteins decreasing over time (HP: 
haptoglobin; HPR: haptoglobin related protein). Cluster 3: proteins increasing over time (HBB: 
Hb-beta; HBA; Hb-alpha; FTH: ferritin heavy-chain; HBD: Hb-delta; CAT: catalase; CA1: 
carbonic anhydrase; FTL: ferritin light-chain).  
B​ Image and absorption spectrum of a (centrifuged) patient-derived CSF sample before (red) and 
after selective removal of Hb (green). Erythrolysed CSF disrupts the dilatory NO-response of 
porcine basilar arteries to MAHMA-NONOate. NO-signaling is restored after removal of Hb 
from the CSF (n=12, group mean±SD).  
C​ Linear regression of CSF-protein ion-intensities before and after passing through the 
haptoglobin-affinity column. 
D ​Tension traces of porcine basilar artery segments immersed in pre-erythrolysed (n=1 patient; 
blue) and in erythrolysed (n=2 patients; red/magenta) CSF from aSAH patients. Baseline and 
after sequential addition of MAHMA-NONOate, haptoglobin, MAHMA-NONOate, and L-NIO. 
Thick lines represent the mean recordings of replicate artery segments.  
E​ Relative changes of the steady-state tension of arteries immersed in patient-derived 
erythrolysed CSF after addition of haptoglobin (equimolar to cell-free Hb). The diamonds 
represent the mean and 95% CI (n=8 patient samples).  
F ​ NO-mediated dilation of arteries immersed in CSF from aSAH patients (n = 8) after 
administration of MAHMA-NONOate. Arteries were sequentially probed in pre-erythrolysed 
CSF (blue), erythrolysed CSF (red) and after the addition of haptoglobin to the erythrolysed CSF 
(green). 
G ​ Size exclusion chromatography of CSF analyzed in 1E/1F before (Hb) and after addition of 
haptoglobin (Hb-Hp). 
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Figure 2: Distribution of hemoproteins after intraventricular infusion in sheep. 
A​ Sagittal reconstruction of T1-weighted MR images from a sheep before and 20 minutes after 
infusion of MnHb. Subtraction of the baseline image from the image after infusion reveals the 
specific signal of MnHb. Binary image of the intracranial MnHb signal. 
B​ Overlay of the signals from MnHb (left) and MnHb-haptoglobin (right) 20 minutes after 
infusion on the corresponding T2-weighted anatomical MR images. 
C​ Schematic diagram indicating the positions of the external ventricular drain (orange) and the 
suboccipital subarachnoid drainage catheter (yellow). 
D​ Three-dimensional reconstruction of the MnHb signal 20 minutes after infusion. 
E​ Visualization of the circle of Willis on digital subtraction angiography, on a photograph of an 
anatomical specimen and on a curved multiplanar reconstruction (MPR) of a T1-weighted MR 
image. The bright (white) signal in the curved MPR represents the infused hemoprotein 
(MnHb-haptoglobin complex in this example), surrounding the posterior communicating artery 
(PCOM) and the basilar artery (BA), as indicated in the coronal view images. The dashed lines 
(1-3) in the curved MPR indicate the location of the coronal sections shown on the right. 
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Figure 3: Hb-induced vasospasm of cerebral arteries and protection by haptoglobin. 
A​ SEC elution profiles of CSF collected from the subarachnoid space at baseline (blue), after 
intraventricular infusion of Hb at t= 0 min (red), and after infusion of haptoglobin at t= 90 min 
(green). Standard elution profiles are shown on the top. 
B​ Angiograms of the middle cerebral artery (MCA) at baseline, 45 minutes after Hb infusion 
(t=45 min) and 45 minutes after haptoglobin infusion (t=135 min). The square in the most right 
image indicates the position of the zoom-images. 
C​ Relative change in diameter of cerebral arteries 60 minutes after infusion of Hb or 
Hb-haptoglobin (ACA: anterior cerebral artery, BA: basilar artery, ICA: internal carotid artery, 
MCA: middle cerebral artery). Diamonds represent the mean and the 95% confidence interval 
(n=4 sheep per group). 
D​ Cumulative analysis of the relative diameter changes of analyzed arterial segments 60 minutes 
after infusion of aCSF (n=32), Hb (n=16) or Hb-haptoglobin (n=16). Colors represent vascular 
areas defined in (C). Group-means were compared by ANOVA, p<0.001. The scheme depicts 
the experimental protocol.  
E​ NO-mediated relaxation profiles (n=8 per condition) of porcine basilar arteries immersed in 
sheep CSF collected after the 60 minutes posttreatment angiograms. Blue line: CSF samples after 
infusion of artificial CSF (CSF-heme 0 µM); red line: CSF samples after infusion of Hb 
(CSF-heme 200-240 µM); green line: CSF samples after infusion of Hb-haptoglobin (CSF-heme 
200-240 µM). Thick lines represent the treatment-group means. Dilatory responses were induced 
with a single bolus of MAHMA-NONOate. 
F ​ Addition of equimolar haptoglobin to the Hb-containing sheep CSF restored the dilatative 
response to MAHMA-NONOate (red line: before haptoglobin addition, same CSF as in (E); 
black line: after haptoglobin addition). Thick lines represent treatment-group means of relaxation 
profiles (n=8).  
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Figure 4: Hb-induced vasospasm after ventricular infusion in sheep. 
A​ Angiograms illustrating segmental vasospasms in major vascular territories, including the 
middle cerebral artery in the lateral projection (arrowheads, upper panel),  the anterior cerebral 
artery (arrow, lower panel) and the middle cerebral artery (asterisk, lower panel) in the 
dorsoventral projection, 60 min after Hb infusion. The demonstrated angiograms are from the 
same experiment shown in Figure 3B. (Identical images are shown in Figure 3B and 4A for the 
dorso-posterior projections at baseline). 
B​ Comparison of illustrative digital subtraction angiography in lateral projection of two sheep 60 
min after infusion of Hb (left) or Hb-haptoglobin complexes (right). Segmental vasospasms of 
the basilar artery (arrow) were apparent 60 minutes after infusion of Hb, whereas no segmental 
vasospasms could be detected in animals infused with Hb-haptoglobin complexes. 
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Figure 5:​ ​The protective function of Hb-haptoglobin in the brain is determined by its 
molecular size. 
A​ Reaction sequence of oxyHb with NO under conditions of excess NO. In a three-step reaction 
oxyHb can scavenge up to three molecules of NO.  
B​ NO-reaction kinetics of Hb (left), Hb-haptoglobin (middle) or polymerized Hb (right). Shown 
are absorbance changes at 405 nm after rapid mixing of NO and oxyHb in a stopped-flow 
spectrophotometer. Estimates of the reaction rates (k1 and k2) were calculated by approximating 
the data with an equation defined by the sum of three exponential functions. 
C​ Tension traces (mean ±SD) of porcine basilar arteries immersed in buffer containing 10µM Hb 
(left; red, n=16), Hb-haptoglobin (middle; green, n=16) or polymerized Hb (right, brown, n=8). 
A bolus of MAHMA NONOate was added (arrowhead) to induce NO-mediated dilation. 
D​ Coronal vibratome sections (2 mm anterior to the bregma) of mouse brains two hours after 
subarachnoid injection of TCO-labeled Hb (left), Hb-haptoglobin (middle) and polymerized Hb 
(right). The false colored images represent the signal intensity of the injected compound after 
post mortem coupling to a fluorophore (tetrazine-5-TAMRA). Intraparenchymal delocalization is 
only observed in the mouse injected with Hb and not after injection of Hb-haptoglobin and 
polymerized Hb (images are representative for n=3 per group). The signal in the area of the 
puncture channel (dashed boxes) serves as a positive control for the injection and labeling 
procedure. 
E​ SEC elution profiles of pure Hb (left; red), Hb-haptoglobin (middle; green) and polymerized 
Hb (right; brown) measured at 414 nm illustrate the different molecular size of the injected 
compounds. 
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Figure 6:​ ​Haptoglobin blocks translocalization of Hb from CSF into the brain parenchyma 
A​ Representative fluorescent images of sheep brain sections (120 µm) after injection of 
TCO-labeled Hb (left panel) and Hb-haptoglobin complexes (right panel), stained for nuclei 
(blue) and the labeled compound (tetrazine-Cy5, yellow). Hb translocates from the ventricular 
system through the ependymal barrier and from the subarachnoid space through the glia limitans 
into the brain interstitial space (images are representative for n=4 animals). This delocalization 
cannot be observed when Hb is bound to haptoglobin (images are representative for n=5 
animals). Fluorescent Hb-haptoglobin complexes can be recognized only along penetrating 
cortical vessels. In section (A), a small amount of Hb-haptoglobin complexes was injected 
directly into the brain parenchyma at the tip of the external ventricular drain catheter, serving as 
a positive control for the staining and imaging procedure (arrow head). Whole-slide scans were 
produced by stitching single images obtained at 10x magnification. Scale bars are indicated in 
the figure. 
B​ Before animals were sacrificed, CSF samples from Hb- and Hb-haptoglobin-treated sheep 
were collected from the subarachnoid space and analyzed by SEC-HPLC, indicating typical 
elution profiles of cell-free Hb and large Hb-haptoglobin complexes. CSF sample of a sheep 
before infusion (blue trace), CSF sample of a sheep infused with Hb (red trace), ​ ​CSF sample of 
a sheep infused with Hb-haptoglobin complexes (green trace). 
C​  The same CSF samples were reacted ex vivo with Cy5 tetrazine and analyzed by SDS page. 
The bands represent a/b globin chains in cell free Hb (Hb) and Hb-haptoglobin complex (HbHp). 
Under non-reducing conditions, the specific ladder pattern of the different type 2-2 haptoglobin 
polymers is clearly visible when analyzed on a gel optimized for high resolution of large proteins 
(7.5%).  
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Figure 7:​ ​Haptoglobin blocks translocation of Hb from CSF into the brain vasculature 
Representative confocal images of small arteries in the periventricular area of the midbrain from 
a sheep after infusion of TCO-labeled Hb (A-D) or Hb-haptoglobin complexes (E-G). The 120 
µm vibratome sections were immunostained for vascular smooth muscle cells (αSMA, green), 
astrocyte end-feet (AQP4, blue) and TCO-labeled Hb (tetrazine-Cy5, red). False-colored images 
(Hb-signal) display only the signal of the labeled hemoprotein from the corresponding image. 
The delocalization of cell-free Hb from the CSF into arterial vessel walls (smooth muscle cell 
layer) and the brain parenchyma (astrocyte covered area) is blocked by haptoglobin (images are 
representative for n=4 animals injected with TCO-Hb, and n=5 animals injected with 
TCO-Hb-haptoglobin complex). Scale bars are 20 µm. 
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Figure 8: ​ ​Mechanism of cell-free Hb toxicity and protection by complex formation of 
Hb with haptoglobin.  
Cell-free Hb is released from lysing erythrocytes in the subarachnoid blood clot after aSAH 
and distributes within the CSF (red). Delocalization of small Hb-dimers (32 kDa) into vessel 
walls of resistance arteries causes macro- and microvascular vasospasms through 
NO-depletion in the vascular wall. Delocalization into the brain parenchyma may cause 
oxidative damage and alter the interstitial microenvironment. Therapeutic haptoglobin 
injected into the ventricular system binds Hb in the subarachnoid space and prevents 
delocalization of the large Hb-haptoglobin complex (>150kDa), thereby attenuating toxicity 
(blue).  
Figure 8
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